News
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
Kinase Inhibitors in Autoimmune Diseases Market Research 2025-2035, Featuring Pfizer, Eli Lilly and Co, Reistone Biopharma, Incyte, BMS, Galapagos, Aclaris Therapeutics, Kadmon, Sanofi, Ono - ...
The global fight between Eli Lilly (NYSE:LLY) and Novo Nordisk (CSE:NOVOb) for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical ...
"Apps, not maps," are the future of Indiana's state parks, according to Department of Natural Resources spokesperson Marty Benson.
With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, intensifying the race for India's booming obesity drug market.
Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘ACCLAIM-Lp (a)’ to evaluate the efficacy of Lepodisiran in reducing major adverse cardiovascular events in adults ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.
Earlier this week, Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion. The acquisition will add Verve’s pipeline of gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results